Predictors of failure and complications of catheter-directed interventions for pulmonary embolism.

Abstract

OBJECTIVE:

Catheter-directed interventions (CDIs) are increasingly performed for acute pulmonary embolism (PE) as they are presumed to provide similar therapeutic benefits to systemic thrombolysis while decreasing the dose of thrombolytic required and the associated risks. This study aimed to identify factors associated with CDI failure and to describe anticipated complications.

METHODS:

Consecutive patients who underwent CDI for massive or submassive PE between 2009 and 2015 were identified; outcomes and complications were retrospectively collected. CDI clinical failure was defined as major bleeding, perioperative stroke or other major adverse procedure-related event, decompensation for submassive or persistent shock for massive PE, need for surgical thromboembolectomy, or in-hospital death. Univariate analysis was used to study the factors associated with CDI failure.

RESULTS:

There were 102 patients who received a CDI during the study period (36 standard catheter thrombolysis, 60 ultrasound assisted, 6 other; age, 59.2 ± 15.9 years; male, 50 [49.0%]; massive PE, 14 [13.7%]). Five patients (4.9%) had a major contraindication and 15 patients (14.7%) had a minor contraindication to systemic thrombolysis. The mean alteplase dose was 28.2 ± 18.8 mg (range, 0-123 mg; three patients had already received systemic lysis). CDI failure occurred in 15 patients (14.7%; 7 in massive PE, 8 in submassive PE). Of these patients, seven had major bleeding events, whereas eight patients decompensated. Ten (9.8%) patients had minor bleeding events (four access related). Factors associated with CDI failure and major bleeding included massive PE, age ≥70 years, and major contraindication to thrombolytics. Both failures and bleeding events were independent of lysis dose and CDI technique.

CONCLUSIONS:

CDIs for acute PE are not risk-free procedures, and their use should be individualized on the basis of a risk-benefit ratio. Particularly for patients with major contraindications to systemic thrombolytics, CDIs should be used selectively. Lytic dose, within the low-volume range administered in CDI, and type of CDI seem to have no impact on adverse events.

• Authors: Efthymios D Avgerinos, Adham N Abou Ali, Nathan L Liang, Elizabeth Genovese, Michael J Singh, Michel S Makaroun, Rabih A Chaer
• Journal: Journal of vascular surgery. Venous and lymphatic disorders (J Vasc Surg Venous Lymphat Disord) Vol. 5 Issue 3 Pg. 303-310 (05 2017) ISSN: 2213-3348 [Electronic] United States
• PMID: 28411694 (Publication Type: Journal Article)
• Copyright: Copyright © 2017 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Chemical References

• Fibrinolytic Agents
• Heparin
• Tissue Plasminogen Activator

Topics

• Acute Disease
• Angioplasty (adverse effects, methods)
• Female
• Fibrinolytic Agents (administration & dosage)
• Hemorrhage (chemically induced)
• Heparin (administration & dosage)
• Hospital Mortality
• Humans
• Male
• Middle Aged
• Prognosis
• Pulmonary Embolism (therapy)
• Retrospective Studies
• Tissue Plasminogen Activator (administration & dosage)
• Treatment Failure
• Ultrasonography, Interventional